Vitamin D and cardiometabolic disorders: a review of current evidence, genetic determinants and pathomechanisms

Clara Marquina, Aya Mousa, Robert Scragg, Barbora de Courten

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Vitamin D deficiency has been implicated in the pathophysiology of cardiometabolic disorders including obesity, type 2 diabetes mellitus, cardiovascular diseases and polycystic ovary syndrome. Despite a large number of experimental and observational studies supporting a role for vitamin D in these pathologies, randomized controlled trials have reported little to no effect of vitamin D supplementation in the prevention or treatment of these disorders, although some results remain ambiguous. Polymorphisms in genes related to vitamin D metabolism, particularly in the vitamin D receptor and binding protein and the metabolizing enzyme 1-α-hydroxylase, have emerged as potential contributors to these divergent results. It is now becoming increasingly recognized that the effects and potential benefits of vitamin D supplementation may vary by several factors including vitamin D deficiency status, ethnicity and/or the presence of genetic variants, which affect individual responses to supplementation. However, these factors have seldom been explored in the available literature. Future trials should consider inter-individual differences and, in particular, should aim to clarify whether certain subgroups of individuals may benefit from vitamin D supplementation in the context of cardiometabolic health.

Original languageEnglish
Pages (from-to)262-277
Number of pages16
JournalObesity Reviews
Issue number2
Publication statusPublished - Feb 2019


  • Cardiometabolic disorders
  • diabetes
  • obesity
  • vitamin D

Cite this